Modeling the epidemiological impact and cost-effectiveness of a combined schoolgirl HPV vaccination and cervical cancer screening program among Chinese women
- 3 December 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Human Vaccines & Immunotherapeutics
- Vol. 17 (4), 1073-1082
- https://doi.org/10.1080/21645515.2020.1832835
Abstract
Human papillomavirus (HPV) infection is common in women and also the main cause of cervical cancer. Based on a dynamic compartmental model, we aimed to evaluate the population impact and cost-effectiveness of strategies that combined cervical cancer screening and HPV schoolgirl vaccination for Chinese women. The effectiveness of interventions was assessed by comparing modeled scenarios to the status quo, where a 3-y cervical cancer screening program remained at a 20% coverage and without a universal HPV vaccination program. Our study demonstrated that increasing screening coverage from 20% to 50% would reduce the high-risk HPV (HR-HPV) prevalence to 5.4%, whereas a universal schoolgirl vaccination program using the quadrivalent vaccine (qHPV) with a coverage of 50% would reduce the prevalence to 2.9% by 2069. Scaling-up the cervical screening coverage to 50% will prevent 16,012 (95% CI: 8,791 to 25,913) Disability-Adjusted Life-Years (DALYs) per year, with an incremental cost-effectiveness ratio (ICER) of US$ 10,958 (95% CI: $169 to $26,973)/DALY prevented. At the current qHPV price, vaccinating 50% of school girls will prevent 13,854 (95% CI: 8,355 to 20,776) DALYs/year, but the corresponding incremental cost-effectiveness ratio (ICER, US$ 83,043, 95% CI: $52,234 to $138,025) exceeds cost-effectiveness threshold (i.e., 3 times GDP per-capita of China: $30,792). The qHPV vaccine requires at least a 50% price reduction to be cost-effective. Vaccinating schoolgirls will result in a large population health benefit in the long term, but such a universal HPV vaccination program can only be cost-effective with a substantial price reduction.
Keywords
Funding Information
- National Natural Science Foundation of China (81950410639)
- Outstanding Young Scholars Funding (3111500001)
- Xi’an Jiaotong University Basic Research and Profession Grant (xtr022019003, xzy032020032)
- Epidemiology modeling and risk assessment (20200344)
- Xi’an Jiaotong University Young Talent Support Grant (YX6J004)
This publication has 42 references indexed in Scilit:
- A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in WomenThe New England Journal of Medicine, 2015
- Implementation of cervical cancer screening and prevention in China--challenges and realityJapanese Journal of Clinical Oncology, 2014
- Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programmeSexually Transmitted Infections, 2014
- Prevalence of human papillomaviruses in semen: a systematic review and meta-analysisHuman Reproduction, 2013
- Recommendations on screening for cervical cancerCMAJ : Canadian Medical Association Journal, 2013
- End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of ageBritish Journal of Cancer, 2011
- Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysisVaccine, 2010
- Human papillomavirus and HPV vaccines: a reviewBulletin of the World Health Organization, 2007
- Quadrivalent Human Papillomavirus VaccineClinical Infectious Diseases, 2007
- Model for Assessing Human Papillomavirus Vaccination StrategiesEmerging Infectious Diseases, 2007